INTRODUCTIONIn this study, we aimed to investigate whether hydroxytyrosol (HT) has a protective effect on corn syrup-induced kidney damage in rats and the role of podocalyxin (PCX) and pentraxin-3 (PTX3) in this possible effect.METHODSRats were divided into four groups with six rats in each group: 1) control, 2) HT, 3) corn syrup, and 4) corn syrup + HT. Rats were given 30% corn syrup added to their drinking water for six weeks. HT was given orally at 4 ml/kg/day, alone and together with corn syrup. PCX and PTX3 in the renal tissue were assessed through histopathological examination. Biochemical parameters were also examined in the sera with the ELISA method.RESULTSIn this study, it was observed that PCX and PTX3 levels, which increased as a result of corn syrup administration, decreased after HT treatment (p < 0.001). The increase in amylase, lipase, and insulin levels because of corn syrup consumption decreased with HT consumption (p = 0.001, p < 0.001, p = 0.003, respectively). It was determined that the increase in erythrocyte extravasation, exudate accumulation, and fibrosis observed in the kidney tissue with corn syrup application decreased as a result of HT application (p < 0.001).CONCLUSIONIt is thought that HT has a protective effect against kidney damage caused by corn syrup and that PCX and PTX3 may play a role in this effect.

01 Oct 2024·Journal of Cardiovascular Translational Research

Pentraxin 3 in Myocarditis: Proof-of-Principle Assessment as a Diagnostic and Prognostic Biomarker

Article

Author: Rovere-Querini, Patrizia ; De Bonis, Michele ; Cianflone, Domenico ; Villatore, Andrea ; Peretto, Giovanni ; Sala, Simone ; Carino, Davide ; Monno, Antonella ; Sciorati, Clara ; Manfredi, Angelo A

Pentraxin 3 (PTX3) is an acute phase protein produced in various tissues in response to microbial and sterile stimuli, which regulates the inflammation outcomes. PTX3 has not been investigated in myocarditis. Our aim was to assess circulating and cardiac tissue expression of PTX3 in 55 patients with myocarditis proven by magnetic resonance and/or endomyocardial biopsy. A major proportion of patients with myocarditis displayed significantly increased plasma PTX3 levels as compared with controls (26/30 vs. 0/10), with higher diagnostic yield than conventional biomarkers in the study group. Cardiac tissue analysis revealed PTX3 expression in all patients (40/40), with viral myocarditis exhibiting higher signal intensity than autoimmune myocarditis, and with a predominant localization in cardiomyocytes. Abnormal plasma PTX3 was associated with systolic dysfunction and heart failure at presentation. Interestingly, patients who recovered by 12 months had higher baseline PTX3 levels. Our preliminary data support the potential use of PTX3 as a biomarker in myocarditis.

01 Apr 2024·Kidney Medicine

Pentraxin-3 and Outcomes in CKD: A Systematic Review and Meta-analysis

Article

Author: Tao, Hui ; Jin, Hao ; Liu, Hongli ; Chen, Hongmei ; Zhou, Zhongwei ; Zhang, Qinglin ; Li, Li

Rationale & ObjectiveLong pentraxin-3 (PTX-3) serves as a biomarker for prognosticating adverse clinical outcomes in individuals with chronic kidney disease (CKD). The objective of the current meta-analysis was to evaluate the prognostic efficacy of PTX-3 in patients with CKD. In addition, we compared the prognostic effectiveness of PTX-3 and the short pentraxin C-reactive protein (CRP) in the identical cohort of patients with CKD.Study DesignA systematic review and meta-analysis.Setting & ParticipantsPatients with CKD treated with or without dialysis.Selection Criteria for StudiesA cohort study with a minimum 1-year follow-up.Data ExtractionRisk measurements, adjusted hazard risk with 95% CI, and modified variables.Analytical ApproachTo aggregate the adjusted effect estimates, a fixed-effects or random-effects model was employed.ResultsNine studies covering 1,825 patients with CKD were selected in the present review. Six of the 9 studies exclusively included patients receiving hemodialysis. The collected findings indicated that patients with CKD in the highest tertile of PTX-3 demonstrated significantly higher risks of all-cause mortality (HR, 1.92; 95% CI, 1.44-2.56), cardiovascular death (HR, 1.98; 95% CI, 1.28-3.05), infectious death (HR, 5.26; 95% CI, 1.60-17.31), and fatal and nonfatal cardiovascular events (HR, 1.81; 95% CI, 1.35-2.42), as compared with those in the lowest tertile. These significant associations with risk were also observed when effect estimates were presented as per unit change in the PTX-3. Moreover, when comparing the prognostic value of PTX-3 and CRP in the same individuals (5 studies covering 904 patients), PTX-3 proved to be a satisfactory predictor of adverse events in these patients, whereas CRP failed to exhibit such predictive capability, regardless of the type of effect estimate used.LimitationsA relatively small sample size and some heterogeneity.ConclusionsPentraxin 3 is associated with adverse events in individuals with CKD and may be a more reliable predictor of adverse clinical events than CRP in this population.

100 Deals associated with Pentraxin 3

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aspergillosis	Discovery	IT	Alfasigma SpA	-
Cytomegalovirus Infections	Discovery	IT	Alfasigma SpA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Pentraxin 3

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation